Results of the clinical and economic analysis of the state of pharmaceutical provision of patients with dementia in Alzheimer’s disease in Ukraine

Aim. To conduct the clinical and economic analysis of state pharmaceutical provision patients with dementia in Alzheimer’s disease Ukraine.
 Materials methods. Both general theoretical (historical, analytical-comparative, systemic, graphical, logical, hypothetical-deductive) applied (clinical-economic, mathematical-statistical) research methods were used.
 Results. It was found that vast majority belonged to socially unprotected segments population. Thus, proportion pensioners 71.0 %, 40 (20.0 %) had disability groups. All patients, without exception, a burdened anamnesis. On average, treated specialized medical institutions for 43.8 bed-days. The sum 548,714.5 UAH (19,072.45 USD) spent on drug these which amounted 2,743.57 (95.36 per one patient. For bed-day, used drugs only 62.64 (2.18 USD). Physicians wrote 2,487 prescriptions (12.4 patient) 128 under international non-proprietary names or 218 taking into account all their trade names. In structure prescriptions, there significant duplication represented by According first level ATC classification system, highest rates prescription frequency group N – Drugs affecting nervous system (861 34.62 %), according second level, from C01 Cardiac therapy (375 15 .08 %). At same time, third positions number occupied groups N05 Psycholeptics (363 14.60 N06 Psychoanaleptics (309 12.42 physicians prescribed 617 (24.81 recommended Clinical Protocol treatment cognitive non-cognitive behavioral disorders due disease. Of N06D Anti-dementia drugs, N06DX Other prescribing (191 physicians), while N06DA Cholinesterase inhibitors 43 times. pathogenetic N06DX01 Memantine (188 30.47 Then, N06DA03 Rivastigmine (34 5.51 N06DA02 Donepezil (6 0.97 followed margin. also leading consumption. volume consumption equal 84,420.2 (2,934,314 USD), accounted 15.39 % total cost 91.76 Medicines use dementia.
 Conclusions. A financial burden associated need requires development implementation effective models resource pharmacotherapy social support neuropsychiatric Ukraine.